On February 10, 2104 a substantial financial deal was announced by Melinta Therapeutics involving their projected blockbuster antibiotic Delafloxacin. A whopping 70 million dollar Series 3 equity financing deal was revealed, with various investors taking part, including Vatera Healthcare Partners. This extraordinary financing will be appropriated largely to advance the continued development, assessment and eventual[…]
Lead Product Candidate Delafloxacin Gains Funding
Antibacterial, Antibiotic, Drug Research & Development API Tags: antibioticMRSA Feb 24, 2014
Telavancin Gains Expanded-Use Approval by the FDA
Antibiotic Tags: antibioticEuropeMRSA Jul 16, 2013
In late June 2013 Telavancin, also known as the brand name antibiotic Vibativ, was approved by the FDA to treat bacterial pneumonia. Marketed by Theravance, Telavancin is an efficacious antibiotic treatment that has been previously approved in both the United States and Europe for bacterial and skin infections. This new approved indication for Telavancin is[…]
Linezolid shown effective against gram-positive bacteria
Antibiotic, Drug Research & Development API Tags: antibioticMRSA Jan 06, 2011
Linezolid is a synthetic antibiotic used for the treatment of serious infections caused by Gram-positive bacteria that are resistant to several other antibiotics. A member of the oxazolidinone class of drugs, Linezolid is active against most Gram-positive bacteria that cause disease, including streptococci, vancomycin-resistant enterococci (VRE), and methicillin-resistant Staphylococcus aureus (MRSA). MRSA is especially troublesome[…]
